[go: up one dir, main page]

MA55885A - Chélateurs macrocycliques et leurs procédés d'utilisation - Google Patents

Chélateurs macrocycliques et leurs procédés d'utilisation

Info

Publication number
MA55885A
MA55885A MA055885A MA55885A MA55885A MA 55885 A MA55885 A MA 55885A MA 055885 A MA055885 A MA 055885A MA 55885 A MA55885 A MA 55885A MA 55885 A MA55885 A MA 55885A
Authority
MA
Morocco
Prior art keywords
methods
macrocyclic chelators
macrocyclic
chelators
Prior art date
Application number
MA055885A
Other languages
English (en)
Inventor
Vadim Dudkin
Shalom Goldberg
John Keith
Rhys Salter
Fengbin Song
Wei Zhang
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA55885A publication Critical patent/MA55885A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA055885A 2019-05-10 2020-05-08 Chélateurs macrocycliques et leurs procédés d'utilisation MA55885A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962846044P 2019-05-10 2019-05-10

Publications (1)

Publication Number Publication Date
MA55885A true MA55885A (fr) 2022-03-16

Family

ID=70804855

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055885A MA55885A (fr) 2019-05-10 2020-05-08 Chélateurs macrocycliques et leurs procédés d'utilisation

Country Status (22)

Country Link
US (2) US11576986B2 (fr)
EP (1) EP3966211A1 (fr)
JP (2) JP7734078B2 (fr)
KR (1) KR20220006613A (fr)
CN (1) CN114127059B (fr)
AU (1) AU2020273654A1 (fr)
BR (1) BR112021022237A2 (fr)
CA (1) CA3139806A1 (fr)
CL (1) CL2021002960A1 (fr)
CO (1) CO2021015713A2 (fr)
CR (1) CR20210556A (fr)
DO (1) DOP2021000233A (fr)
EA (1) EA202193076A1 (fr)
EC (1) ECSP21089217A (fr)
IL (1) IL287909A (fr)
MA (1) MA55885A (fr)
MX (1) MX2021013667A (fr)
PE (1) PE20220935A1 (fr)
PH (1) PH12021552791A1 (fr)
SG (1) SG11202112100PA (fr)
UA (1) UA129220C2 (fr)
WO (1) WO2020229974A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179117B2 (en) 2016-06-23 2019-01-15 Cornell University Double targeted constructs to affect tumor kill
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
US20220016277A1 (en) 2018-11-20 2022-01-20 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
CA3139806A1 (fr) 2019-05-10 2020-11-19 Janssen Biotech, Inc. Chelateurs macrocycliques et leurs procedes d'utilisation
PL3966206T3 (pl) 2019-05-10 2024-01-29 Deciphera Pharmaceuticals, Llc Heteroaryloaminopirymidynoamidowe inhibitory autofagii i sposoby ich zastosowania
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
AU2020297422B2 (en) 2019-06-17 2024-03-21 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
WO2021250240A1 (fr) * 2020-06-12 2021-12-16 Orano Dérivé de diaza-18-crown-6 utile pour chélater le radium, conjugué et chélate de radium comprenant ce dérivé et utilisations correspondantes
CA3200975A1 (fr) * 2020-11-10 2022-05-19 Janssen Biotech, Inc. Composes macrocycliques et leurs procedes d'utilisation
KR20230142482A (ko) 2021-01-27 2023-10-11 얀센 바이오테크 인코포레이티드 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는면역접합체 및 이의 용도
EP4317152A4 (fr) * 2021-03-26 2025-03-26 Nihon Medi-Physics Co., Ltd. Composé, procédé de production et procédé de stockage d'un composé, procédé de production d'un agent de ciblage et composition
US20240207463A1 (en) * 2021-03-31 2024-06-27 Nihon Medi-Physics Co., Ltd. Radioactive complex of anti-egfr antibody, and radiopharmaceutical
JP2024521784A (ja) 2021-05-27 2024-06-04 ヤンセン バイオテツク，インコーポレーテツド 前立腺がんの治療のための組成物及び方法
WO2023191839A2 (fr) * 2021-08-02 2023-10-05 Rayzebio, Inc. Compositions stabilisées de radionucléides et leurs utilisations
JP2024125438A (ja) * 2021-08-03 2024-09-19 住友化学株式会社 放射性金属錯体及びその製造方法、並びに放射性金属捕捉剤
CA3230346A1 (fr) 2021-08-27 2023-03-02 Janssen Biotech, Inc. Anticorps anti-psma et leurs utilisations
US20230122503A1 (en) * 2021-08-27 2023-04-20 Janssen Biotech, Inc. Anti-psma radioconjugates and uses thereof
AU2022354706A1 (en) * 2021-09-29 2024-04-11 The University Of Melbourne Macrocycle containing compounds and radiolabelled complexes thereof, as ligands in targeted radiotherapy applications
JP2024542168A (ja) * 2021-11-09 2024-11-13 ヤンセン バイオテツク，インコーポレーテツド 大員環化合物及びその製造方法
US20250145646A1 (en) * 2021-11-09 2025-05-08 Janssen Biotech, Inc. Macrocyclic compounds and diagnostic uses thereof
JP2025504907A (ja) 2022-01-26 2025-02-19 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用
JP2023135733A (ja) * 2022-03-16 2023-09-29 Ｊｆｅエンジニアリング株式会社 ジルコニウム錯体およびその合成方法
CN114656422B (zh) * 2022-04-22 2023-05-23 重庆理工大学 一种新型氮杂冠醚化合物及其阳离子脂质体、制备方法与应用
CN114874214B (zh) * 2022-05-31 2023-03-21 南京航空航天大学 可偶联巯基的双功能大环螯合剂衍生物及其制备方法
CN114949259B (zh) * 2022-07-11 2023-09-19 重庆理工大学 一种氮杂冠醚结构的基因递送载体及其制备方法和应用
TW202530249A (zh) 2023-09-29 2025-08-01 美商雅克提斯腫瘤學公司 小蛋白、結合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE353450T1 (de) * 1988-06-24 1990-09-06 The Dow Chemical Co., Midland, Mich. Macrocyclische bifunktionelle chelatbildner, komplexe davon und ihre konjugierten antikoerper.
WO2000059896A1 (fr) 1999-03-23 2000-10-12 The United States Of America, Represented By The Secretary, Department Of Health And Human Services 225ac-heha et composes, procedes de synthese et procedes d'utilisation correspondants
EP2595967B1 (fr) 2010-07-23 2016-03-23 University Of Delaware Ligature tétrazine-trans-cyclooctène pour la construction rapide de sondes marquées par un radionucléide
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
LT3071595T (lt) 2013-11-19 2019-05-10 Fredax Ab Humanizuotas anti-kalikreino-2 antikūnas
UA126788C2 (uk) 2015-08-11 2023-02-08 Ґалера Лебз, Елелсі Комплексні сполуки, що містять макроциклічне кільце пентаази, які мають пероральну біодоступність
US12048753B2 (en) 2015-10-01 2024-07-30 Whitehead Institute For Biomedical Research Labeling of antibodies
FR3045606B1 (fr) 2015-12-18 2019-04-05 Ecole Normale Superieure De Lyon Complexes de lanthanide pour la cristallisation de macromolecules biologiques et la determination de leur structure cristallographique
MX386103B (es) 2016-04-22 2025-03-18 Astrazeneca Ab Inhibidores de mcl-1 y metodos de uso de los mismos.
WO2018187631A1 (fr) * 2017-04-05 2018-10-11 Cornell University Constructions trifonctionnelles avec pharmacocinétiques réglables utiles dans les thérapies d'imagerie et antitumorales
CN109803973B (zh) 2016-08-10 2022-05-24 癌靶技术有限责任公司 螯合psma抑制剂
JP2018068834A (ja) * 2016-11-01 2018-05-10 オリンパス株式会社 走査型内視鏡および走査型内視鏡の製造方法
WO2018183906A1 (fr) * 2017-03-30 2018-10-04 Cornell University Complexes macrocycliques de radionucléides émetteurs alpha et leur utilisation en radiothérapie ciblée contre le cancer
JP2021502418A (ja) * 2017-11-04 2021-01-28 アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド ポリペプチドを修飾するための組成物及び方法
CN111491670A (zh) 2017-12-18 2020-08-04 詹森生物科技公司 多肽的放射性标记
JOP20200303A1 (ar) 2018-05-24 2020-11-23 Janssen Biotech Inc عوامل ربط psma واستخداماتها
US20220016277A1 (en) 2018-11-20 2022-01-20 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
BR112021010799A2 (pt) 2018-12-03 2021-08-24 Fusion Pharmaceuticals Inc. Terapia combinada com radioimunoconjugados e inibidor do ponto de verificação
IL287938B2 (en) 2019-05-10 2025-07-01 Takeda Pharmaceuticals Co Antibody-drug conjugates
CA3139806A1 (fr) 2019-05-10 2020-11-19 Janssen Biotech, Inc. Chelateurs macrocycliques et leurs procedes d'utilisation
CA3200975A1 (fr) 2020-11-10 2022-05-19 Janssen Biotech, Inc. Composes macrocycliques et leurs procedes d'utilisation
KR20230142482A (ko) 2021-01-27 2023-10-11 얀센 바이오테크 인코포레이티드 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는면역접합체 및 이의 용도
JP2024542168A (ja) 2021-11-09 2024-11-13 ヤンセン バイオテツク，インコーポレーテツド 大員環化合物及びその製造方法
US20250145646A1 (en) 2021-11-09 2025-05-08 Janssen Biotech, Inc. Macrocyclic compounds and diagnostic uses thereof

Also Published As

Publication number Publication date
CN114127059B (zh) 2024-09-24
CA3139806A1 (fr) 2020-11-19
CN114127059A (zh) 2022-03-01
SG11202112100PA (en) 2021-11-29
JP2025176045A (ja) 2025-12-03
US20200353105A1 (en) 2020-11-12
JP7734078B2 (ja) 2025-09-04
EP3966211A1 (fr) 2022-03-16
MX2021013667A (es) 2022-01-31
CO2021015713A2 (es) 2021-11-30
US12453785B2 (en) 2025-10-28
AU2020273654A1 (en) 2021-11-25
UA129220C2 (uk) 2025-02-12
US11576986B2 (en) 2023-02-14
DOP2021000233A (es) 2022-07-31
CL2021002960A1 (es) 2022-06-24
ECSP21089217A (es) 2022-01-31
WO2020229974A1 (fr) 2020-11-19
PH12021552791A1 (en) 2022-09-05
CR20210556A (es) 2021-12-17
BR112021022237A2 (pt) 2022-03-29
JP2022532157A (ja) 2022-07-13
EA202193076A1 (ru) 2022-02-16
KR20220006613A (ko) 2022-01-17
US20230110178A1 (en) 2023-04-13
IL287909A (en) 2022-01-01
PE20220935A1 (es) 2022-05-31

Similar Documents

Publication Publication Date Title
MA55885A (fr) Chélateurs macrocycliques et leurs procédés d'utilisation
MA55136A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA54538A (fr) Inhibiteurs d'apol1 et leurs procédés d'utilisation
MA54261A (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP3968999A4 (fr) Inhibiteurs de fgfr et leurs procédés d'utilisation
MA55890A (fr) Modulateurs de thr-beta et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
EP3911640A4 (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
MA54594A (fr) Stéroïdes neuroactifs et leurs procédés d'utilisation
EP3684364A4 (fr) Pyridazinones et leurs procédés d'utilisation
EP4022069A4 (fr) Arn circulaires modifiés et leurs procédés d'utilisation
MA71645A (fr) Pyridazinones et leurs procédés d'utilisation
EP3416634A4 (fr) Agents immunomodulateurs et leurs procédés d'utilisation
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
EP3790572A4 (fr) Variants du récepteur de l'activine de type iia et leurs procédés d'utilisation
EP3917508A4 (fr) Activateurs de la mitofusine et leurs procédés d'utilisation
EP3962481A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3941475A4 (fr) Pyridazinones et leurs procédés d'utilisation
MA51837A (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
MA56457A (fr) Modulateurs de hsd17b13 et leurs procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3635000A4 (fr) Manabodies et procédés d'utilisation
EP4034605A4 (fr) Compositions de polissage et leurs procédés d'utilisation
EP3953385A4 (fr) Anticorps cd19 et leurs procédés d'utilisation